D000911Chemicals & DrugsD12.776.124.486.485.114.224D12.776.124.790.651.114.224D12.776.377.715.548.114.22433713760.622785Antibodies, Monoclonalprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson7.816310.00305666337research area of0.9920610.0124831439subject area forMedicine-GastroenterologyMedicine-Hematology and OncologyMarina ChiaraGarassinoMarina Chiara Garassino41.7886000000000087.598699999999994025Garassino, Marina ChiaraProfessor34269818San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, Mateos MV, Touzeau C, Jakubowiak A, Usmani SZ, Cook G, Cavo M, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJBloodSustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022 01 27; 139(4):492-501.Blood2022-01-27T00:00:002022Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.34991107Liu J, Bratton E, Yu X, Ladbury C, Wagner J, West H, Massarelli E, Salgia R, Pathak R, Villaflor V, Villalona-Calero M, Amini AAmerican journal of clinical oncologyPatterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC). Am J Clin Oncol. 2022 02 01; 45(2):49-54.Am J Clin Oncol2022-02-01T00:00:002022Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).MedicineUniversity of Chicago37801329Paz-Ares L, Garassino MC, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A, Trukhin D, Hochmair MJ, Özgüroglu M, Ji JH, Statsenko G, Conev N, Bondarenko I, Havel L, Losonczy G, Xie M, Lai Z, Godin-Heymann N, Mann H, Jiang H, Shrestha Y, Goldman JWClinical cancer research : an official journal of the American Association for Cancer ResearchDurvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024 02 16; 30(4):824-835.Clin Cancer Res2024-02-16T00:00:002024Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.RaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, Professor37804505Borowska MT, Boughter CT, Bunker JJ, Guthmiller JJ, Wilson PC, Roux B, Bendelac A, Adams EJCell reportsBiochemical and biophysical characterization of natural polyreactivity in antibodies. Cell Rep. 2023 10 31; 42(10):113190.Cell Rep2023-10-05T00:00:002023Biochemical and biophysical characterization of natural polyreactivity in antibodies.37855076Mena Lora AJ, Echeverria SL, Lindsey B, Li E, Sanchez L, Truesdell T, Takhsh E, Lavani R, Burgos RInfection control and hospital epidemiologyFeasibility and impact of a monoclonal antibody infusion program in reaching vulnerable underserved communities. Infect Control Hosp Epidemiol. 2023 10; 44(10):1690-1692.Infect Control Hosp Epidemiol2023-04-04T00:00:002023Feasibility and impact of a monoclonal antibody infusion program in reaching vulnerable underserved communities.Russell D.CohenRussell D. Cohen41.78927490000000-87.601250000000002354Cohen, Russell D.ProfessorKennethGordonKenneth Gordon41.78927490000000-87.60125000000000340Gordon, KennethStephenHanauerStephen B. Hanauer41.78927490000000-87.60125000000000660Hanauer, StephenEmeritus/Emeritatrue1true1Emeritus/EmeritaEmeritus/Emeritatrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1ProfessorProfessor